Cultivated meat supplier Meatly has raised funding to build the largest production facility of its kind in Europe.
Meatly is the first company in Europe to sell cultivated meat commercially, having secured UK regulatory authorisation in 2024 and run a retail trial with Pets at Home in 2025. Its current focus is the pet food market, and the new facility will allow Meatly to continually produce cultivated chicken at scale for UK retailers.
The new 20,000-litre pilot bioreactor facility in London is being funded by a £10.4m Series A round backed by three new institutional investors – Oyster Bay Venture Capital, Clean Growth Fund, and JamJar Investments – joining the £7 million in seed funding provided by founding investors Agronomics and Pets at Home. Fit-out for the facility has already begun, with product releases expected in 2027.
Meatly chief executive Owen Ensor said: “This investment marks a powerful endorsement not just of Meatly, but of Britain’s foodtech and biotech sectors. Meatly has one focus – to make commercially viable cultivated meat a reality.
“Over the last four years, Meatly’s pioneering team has systematically focused on reducing key costs and building the strongest possible technical foundation for growth. Now we have our own industry-leading technology, and we are ready to scale. This step will allow us to prove commercial viability at scale and start to continually produce Meatly Chicken for the UK pet food market.”
Connor Duffy, investment manager at Clean Growth Fund, added: “Rethinking how we produce protein is an essential part of tackling the climate crisis. We’ve invested in Meatly because they are showing it’s possible to produce real meat cost-competitively and with a fraction of the environmental impact.”
